Key result
Anacetrapib reduces HDL apoA-I fractional clearance rate by ~18%, increasing HDL apoA-I levels.
RCT (n=39)
Double-blind
Randomized, fixed-sequence
Answers are grounded in this paper and cite their sources.
Randomized double-blind trial shows anacetrapib slows HDL apoA-I and CETP clearance, indicating reduced protein removal drives drug-induced increases in HDL.
OBJECTIVE: Anacetrapib (ANA), an inhibitor of cholesteryl ester transfer protein (CETP) activity, increases plasma concentrations of high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-I (apoA)-I, apoA-II, and CETP. The mechanisms responsible for these treatment-related increases in apolipoproteins and plasma CETP are unknown. We performed a randomized, placebo (PBO)-controlled, double-blind, fixed-sequence study to examine the effects of ANA on the metabolism of HDL apoA-I and apoA-II and plasma CETP. APPROACH AND RESULTS: Twenty-nine participants received atorvastatin (ATV) 20 mg/d plus PBO for 4 weeks, followed by ATV plus ANA 100 mg/d for 8 weeks (ATV-ANA). Ten participants received double PBO for 4 weeks followed by PBO plus ANA for 8 weeks (PBO-ANA). At the end of each treatment, we examined the kinetics of HDL apoA-I, HDL apoA-II, and plasma CETP after D3-leucine administration as well as 2D gel analysis of HDL subspecies. In the combined ATV-ANA and PBO-ANA groups, ANA treatment increased plasma HDL-C (63.0%; P<0.001) and apoA-I levels (29.5%; P<0.001). These increases were associated with reductions in HDL apoA-I fractional clearance rate (18.2%; P=0.002) without changes in production rate. Although the apoA-II levels increased by 12.6% (P<0.001), we could not discern significant changes in either apoA-II fractional clearance rate or production rate. CETP levels increased 102% (P<0.001) on ANA because of a significant reduction in the fractional clearance rate of CETP (57.6%, P<0.001) with no change in CETP production rate. CONCLUSIONS: ANA treatment increases HDL apoA-I and CETP levels by decreasing the fractional clearance rate of each protein.
No takes yet. Share an insight, caveat, or question.
Reyes‐Soffer et al. (2016) conducted an RCT in Lipoprotein metabolism (HDL apoA-I, apoA-II, and plasma CETP kinetics) (n=39). Anacetrapib vs. Placebo (with or without atorvastatin 20 mg/d) was evaluated on Fractional clearance rate of HDL apolipoprotein A-I (-18.2% change, p=0.002). Anacetrapib /d increased HDL apoA-I and CETP by reducing their fractional clearance rates by 18.2% and 57.6%, respectively.
Synapse has enriched 10 related papers. Consider them for comparative context: